| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: an extraordinary paradigm shift
|
Epstein, Murray
|
|
|
12 |
1 |
p. 1-6
|
article
|
| 2 |
Clinical perspective—evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes
|
Rossing, Peter
|
|
|
12 |
1 |
p. 27-35
|
article
|
| 3 |
Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists—unmet needs and underserved patient cohorts
|
Epstein, Murray
|
|
|
12 |
1 |
p. 69-75
|
article
|
| 4 |
Editorial Board
|
|
|
|
12 |
1 |
p. A1
|
article
|
| 5 |
Epidemiology of chronic kidney disease: an update 2022
|
Kovesdy, Csaba P.
|
|
|
12 |
1 |
p. 7-11
|
article
|
| 6 |
Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms
|
Bauersachs, Johann
|
|
|
12 |
1 |
p. 19-26
|
article
|
| 7 |
Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease
|
Nakamura, Toshifumi
|
|
|
12 |
1 |
p. 12-18
|
article
|
| 8 |
Subscription Information
|
|
|
|
12 |
1 |
p. A2
|
article
|
| 9 |
Table of Contents
|
|
|
|
12 |
1 |
p. A4
|
article
|
| 10 |
The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targets
|
Hollenberg, Morley D.
|
|
|
12 |
1 |
p. 48-62
|
article
|
| 11 |
The renin–angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts
|
Ferrario, Carlos M.
|
|
|
12 |
1 |
p. 36-47
|
article
|
| 12 |
The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis
|
Luther, James M.
|
|
|
12 |
1 |
p. 63-68
|
article
|
| 13 |
Title Page
|
|
|
|
12 |
1 |
p. A3
|
article
|
Journal description